Table 1.

A global projection (hypothesized) of acute flares of symptoms in patients with chronic spontaneous urticaria and angio‐oedema (CSU/A) based on 1% point prevalence. Population data are based on United Nations estimates for individuals aged ≥ 18 years in 2020¹⁰

	Projected number of patients with CSU/A	Absolute number of patients experiencing postvaccine flares of CSU/A symptoms based on a hypothesized incidence of
		0·5%	1%	5%	10%
By World Bank income group
High‐income countries	10 107 600	50 538	101 076	505 380	1 010 760
Middle‐income countries	40 248 360	201 242	402 484	2 012 418	4 024 836
Low‐income countries	4 034 480	20 172	40 345	201 724	403 448
By continent
Africa	7 144 420	35 722	71 444	357 221	714 442
Asia	33 372 970	166 865	333 730	1 668 649	3 337 297
Europe	6 047 020	30 235	60 470	302 351	604 702
Latin America and the Caribbean	4 657 010	23 285	46 570	232 851	465 701
Northern America	2 882 310	14 412	28 823	144 116	288 231
Oceania	307 540	1538	3075	15 377	30 754